EPISODE · Dec 21, 2018 · 8 MIN
Gemtuzumab Ozogamicin a Safe, Tolerable Option for Patients With Relapsed/Refractory AML
from Oncology Learning Network · host HMP Global
Gemtuzumab Ozogamicin a Safe, Tolerable Option for Patients With Relapsed/Refractory AML by HMP Global
Embed this episode
Ready to play
Gemtuzumab Ozogamicin a Safe, Tolerable Option for Patients With Relapsed/Refractory AML
0:00
8:47
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Oncology Learning Network?
This episode is 8 minutes long.
When was this Oncology Learning Network episode published?
This episode was published on December 21, 2018.
Can I download this Oncology Learning Network episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!